Article
High-Dose Methylphenidate and Carboxylesterase 1 Genetic Variability in Patients With Attention-Deficit/Hyperactivity Disorder: A Case Series.
Journal of clinical psychopharmacology - 1 Jan 2000
Westerkamp Andrie C, Pereira Rob Rodrigues, Huitema Vera R, Kouwert Ester A M, Matic Maja, van Schaik Ron H N, Punt Nieko, Schoevers Robert A, Touw Daan J
Abstract excerpt
PURPOSE/BACKGROUND: Methylphenidate (MPH) is widely used to reduce symptoms of attention-deficit/hyperactivity disorder. Methylphenidate is metabolized by the carboxylesterase 1 (CES1) enzyme. Some patients need a very high dose of MPH to reach desired clinical effects, without having adverse effects. This may be due to differences in MPH pharmacokinetics (PK), potentially caused by DNA variants in CES1 , the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
